Introduction
============

Lung cancer is the most frequent type of primary cancer for men in China, and it has the highest mortality rate for any type of cancer worldwide ([@b1-ol-0-0-7622]). Despite the lower incidence of lung cancer than breast cancer for women, its mortality rate is also the highest for women ([@b2-ol-0-0-7622]). There are three major types of lung cancer, including non-small cell lung cancer (NSCLC), small cell lung cancer and carcinoid lung cancer. NSCLC is the most common type of lung cancer, accounting for 85% of all lung cancer cases. NSCLC can be further divided into three major histological subtypes: Adenocarcinoma (ADC), squamous cell carcinoma (SCC) and large cell carcinoma (LCC) ([@b3-ol-0-0-7622],[@b4-ol-0-0-7622]). Patients with lung cancer do not always present distinct symptoms, and are commonly diagnosed at an advanced stage or after the primary cancer has metastasized. This causes a poor prognosis and high mortality rate for patients with lung cancer ([@b4-ol-0-0-7622]). The prevention and treatment of lung cancer urgently requires improvement through further understanding the molecular origins and development of the disease.

An increased exposure to smoking is associated with an increased risk of developing NSCLC ([@b5-ol-0-0-7622],[@b6-ol-0-0-7622]). However, only 10--24% of smokers develop NSCLC, indicating that other environmental and genetic factors also contribute to NSCLC development ([@b7-ol-0-0-7622],[@b8-ol-0-0-7622]). Mutations in the epidermal growth factor receptor (EGFR) gene are common in NSCLC patients, with mutation rates differing in males, females, smokers and non-smokers ([@b9-ol-0-0-7622],[@b10-ol-0-0-7622]). EGFR mutations affect the EGF-EGFR-RAS-RAF signaling pathway, and are usually driver mutations for NSCLC development ([@b11-ol-0-0-7622]). EGFR is, therefore, one of the most important targets in NSCLC treatment. Small molecule tyrosine kinase inhibitors (TKIs) that target EGFR, including gefitinib and erlotinib, have significantly improved the overall survival rate of patients with EGFR-activating mutations. The efficacy of TKI drugs differs depending on the region of the EGFR kinase domain in which the mutation is located ([@b12-ol-0-0-7622],[@b13-ol-0-0-7622]). Among the NSCLC patients with EGFR mutations, the overall response rate for treatment with gefitinib is \~75%, with a progression-free survival time of 9--13 months ([@b14-ol-0-0-7622]). Despite their low prevalence, new targetable EGFR mutations may improve the treatment and elongate the overall survival rate of patients with NSCLC.

In this study, EGFR mutations were detected in 354 patients with NSCLC of Chinese ethnicity by sequencing exons 18--21 from tumor samples. Further analysis was performed to determine the association between EGFR mutations and other variables, including age, gender, smoking status, and histology groups. A novel EGFR mutation, M793K, was detected in 7 patients with potential resistance to gefitinib.

Patients and methods
====================

### Patients

A total of 354 patients with NSCLC at the 307th Hospital of the Chinese People\'s Liberation Army (Beijing, China) and the General Hospital of the Chinese People\'s Liberation Army (Beijing, China) were enrolled in this study between November 2012 and April 2016. Informed consent was obtained from all individual participants included in the study, which was approved by the Ethics Committee of the Affiliated Hospital of Academy of Military Medical Sciences and the Ethics Committee of the General Hospital of Chinese People\'s Liberation Army. Formalin-fixed and paraffin-embedded (FFPE) tumor samples were prepared from primary surgical or biopsy specimens from patient lung tissue. All FFPE tissue specimens were identified by pathologists as primary NSCLC.

### Detection of EGFR mutations

Tumor genomic DNA from each FFPE sample was extracted using the ALLPrep DNA/RNA FFPE kit (Qiagen, Inc., Valencia, CA, USA) according to the manufacturer\'s instructions. The DNA samples were examined for purity and concentration, and were diluted to a working concentration of 10 ng/µl. The detection of EGFR mutations was performed using Sanger sequencing with the ABI 3130 genetic analyzer (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The primers used are listed in [Table I](#tI-ol-0-0-7622){ref-type="table"} and were generated according to the manufacturer\'s protocol (Tianyi Huiyuan LLC, Beijing, China).

### Statistical analysis

χ^2^ tests for univariate analysis were performed to investigate the association between EGFR mutation frequency and clinicopathological features. Associations between EGFR mutation status and sex, age, smoking history and clinicopathological characteristics were further evaluated by multivariate logistic regression analysis. The adjusted odds ratio (OR) and 95% confidence interval (CI) were then identified. Associations between sex, age, smoking history and pathology with specific mutations were analyzed using an exact binomial test. A two-sided P\<0.05 was considered to indicate a statistically significant difference. All statistical analysis was performed using R (version 3.2.3; <http://www.r-project.org/>).

### 3D model protein building and EGFR-gefitinib affinity estimation

The EGFR kinase domain with M793K mutation was constructed using structure 2JIT from the Protein Data Bank (originally the EGFR kinase domain including a T790M mutation; 3.1 Å, complete from 696--986) as a template using the SWISS-model server (<https://swissmodel.expasy.org/>). The structure for wild type EGFR domain was from 1M14 from the Protein Data Bank (2.6 Å, complete from 672--960). SWISS-DOCK (<http://www.swissdock.ch/>) was used to test the binding energy of gefitinib (from ZINC; 19632614) to the 3 structures using the CHARMM energy field method.

Results
=======

### Demographic profile of NSCLC patients

The EGFR mutation status was analyzed in 354 NSCLC patients. Of these patients, 43.22% were female and 56.78% were male. The patient age ranged from 32--92 years, with a median age of 62. A total of 59.04% of the patients were ≥60 years old and 40.96% \<60 years old. Of the 354 patients, 50.85% had never smoked. Pathological analysis revealed that 81.92% of the samples were from ADC, 16.95% from SCC, and 1.13% from LCC ([Table II](#tII-ol-0-0-7622){ref-type="table"}).

### EGFR mutation distributions

EGFR mutations were identified in 48.02% (170) patients, with a single mutation identified in the majority of these patients (121 out of 170, 71.18%). Patients with more than one EGFR mutation were relatively uncommon: 13.53% (23/170) exhibited double mutations, 6.74% (11/170) triple mutations, 2.94% (5/170) quadruple mutations, 1.76% (2/170) quintuple mutations, 1.76% (3/170) sextuple mutations, 1.18% (2/170) septuple mutations and 1.18% (3/170) nonuple mutations. Of the 170 patients with EGFR mutations, 97 patients had point mutations in exon 19 and 92 in exon 21. The remaining mutations were located in exon 20 (58 patients) and exon 18 (38 patients). The most common mutation in exon 19 was E746-A750del (30 patients), and the most common in exon 21 was L858R (36 patients). In exon 20, Q787Q and M793K were detected in 11 and 7 patients, respectively ([Table III](#tIII-ol-0-0-7622){ref-type="table"}).

### Associations between EGFR mutation occurrence and clinicopathological features

Patients were divided into two groups (with and without EGFR mutations) for clinicopathological feature association analysis ([Fig. 1](#f1-ol-0-0-7622){ref-type="fig"}). Multivariate logistic regression analysis revealed that EGFR mutations were more frequently detected in females than in males (female vs. male; 60.13 vs. 38.81%; adjusted OR, 1.93; 95% CI, 1.07--3.51; P=0.029). Patients ≥60 were more likely to have EGFR mutations than patients \<60 years old (\<60 vs. ≥60; 58.62 vs. 40.67%; adjusted OR, 1.87; 95% CI, 1.20--2.92; P=0.006). ADC patients had a higher chance of exhibiting EGFR mutations than non-ADC patients (ADC vs. non-ADC; 52.76 vs. 26.56%; adjusted OR, 2.35; 95% CI, 1.28--4.50; P=0.007). There was no significant difference between smokers and non-smokers in the EGFR mutation rate (smokers vs. non-smokers; 55.56 vs. 40.23%; adjusted OR, 1.02; 95% CI, 0.56--1.82; P=0.952). However, if only patients \<60 are considered, EGFR mutation rate in non-smokers was significantly higher than in smokers (non-smokers vs. smokers; 66.27 vs. 48.39%; adjusted OR, 2.10; 95% CI, 1.07--4.11; P=0.046). Similar results were identified between non-smokers and smokers with ADC (non-smokers with ADC vs. smokers with ADC; 58.64 vs. 45.31%; adjusted OR, 1.71; 95% CI, 1.07--2.73; P=0.032; [Table IV](#tIV-ol-0-0-7622){ref-type="table"}).

### Association between specific mutations and clinicopathological features

The association between specific mutations and clinicopathological features was analyzed using an exact binomial test. Between patients with ADC and SCC, the frequencies of E746_A750del, Q787Q and L858R mutations were significantly different (P\<0.001). Furthermore, the L858R mutation was significantly more frequent in smokers than in non-smokers. No significant associations were identified between specific mutations and other clinicopathological features ([Fig. 1](#f1-ol-0-0-7622){ref-type="fig"}).

### Analysis of the M793K mutation

The EGFR mutation M793K was detected in 7 out of 354 patients with NSCLC, including five smokers. No KRAS mutations or EGFR drug-resistance mutations, including T790M or C797S, were detected in these 7 patients. However, the follow-up information for these patients demonstrated that they responded poorly to treatment with gefitinib. Similar to the T790M mutation, M793K also occurs in the inhibitor-binding cleft between the N-lobe and C-lobe of the EGFR kinase domain, indicating that it is likely to be a novel drug-resistance mutation.

Gefitinib was always identified in the cleft between the N-lobe and C-lobe in the 3D models of wild type EGFR, EGFR with T790M and EGFR with M793K ([Fig. 2](#f2-ol-0-0-7622){ref-type="fig"}). A total of 256 binding poses for wild type EGFR, 256 for EGFR with T790M and 252 for EGFR with M793K were determined. The full fitness scores between gefitinib and EGFR ranged from −2196.87 to −2160.79 kcal/mol for wild type EGFR, from −1791.71 to −1756.65 kcal/mol for M793K-mutated EGFR, and from −1805.53 to-1759.77 kcal/mol for T790M-mutated EGFR ([Table V](#tV-ol-0-0-7622){ref-type="table"}). The reduced affinity between gefitinib and EGFR with M793K may be reflective of the gefitinib drug resistance of patients with M793K.

Discussion
==========

EGFR mutations were detected in 170 out of the 354 patients with NSCLC of Chinese ethnicity by Sanger sequencing of EGFR exons 18--21. Associations between EGFR mutation occurrence and patient clinicopathological factors were further analyzed. A new EGFR mutation, M793K, was detected and predicted to be a TKI resistance mutation.

Of the 354 NSCLC patients, 43.22% were female and 56.78% were male, 50.85% patients were non-smokers and 49.15% were smokers. Pathological slides were collected and diagnosed for all patients, with 81.92% samples identified as ADCs, 16.95% as SCCs and 1.13% as LCCs. It is generally accepted that the median age of patients with NSCLC worldwide is 71 ([@b15-ol-0-0-7622]). The lower median age in this study (62 years), supports the indication that the median age of patients with NSCLC in Asia has lowered ([@b9-ol-0-0-7622],[@b16-ol-0-0-7622],[@b17-ol-0-0-7622]).

Less than 30% patients had multiple EGFR mutations in the present study. The most common mutations were L858R (36 patients) and E746-A750del (30 patients), which is consistent with previous reports ([@b9-ol-0-0-7622],[@b10-ol-0-0-7622]). Multivariate logistic regression analysis revealed that EGFR mutations happened more frequently in females (P=0.029), older patients (≥60 years old; P=0.006) and ADC (P=0.007), which consolidates the results of previous reports ([@b18-ol-0-0-7622]--[@b21-ol-0-0-7622]). There was no significant difference in the EGFR mutation rate between smokers and non-smokers (P=0.952). However, in patients \<60 years old, univariate analysis revealed that non-smokers are much more likely to have EGFR mutations than smokers (P=0.046). This was also true for patients with ADC, whereas non-smokers exhibited a higher EGFR mutation rate than smokers (P=0.032).

A significant association was observed between histology type and specific EGFR mutation rates as the frequencies of E746_A750del, Q787Q and L858R mutations were significantly different between patients with ADC and patients with SCC (P\<0.001). Smokers were also more likely to have the L858R mutation than non-smokers.

The EGFR gene encodes a receptor protein that dimerizes upon ligand binding, activating tyrosine kinase activity and receptor phosphorylation. The kinase activity of EGFR can be increased by mutations to EGFR, inducing the hyperactivation of downstream pro-survival signaling pathways ([@b22-ol-0-0-7622]). Initial studies on the TKIs gefitinib (Iressa) and erlotinib (Tarceva) demonstrated biological and clinical significance in a subset of lung cancers ([@b23-ol-0-0-7622]). Further investigation demonstrated that patients with advanced NSCLC and EGFR-activating mutations (particularly exon 19 deletions, L858R in exon 21, and G719X in exon 18) demonstrated the highest response rates to these TKIs ([@b24-ol-0-0-7622]). However, over 6--12 months of treatment, the majority of tumor cells gained resistance to EGFR-TKIs through a secondary mutation. Previous studies reported that T790M occurs in 50% of EGFR-mutated patients with TKI resistance ([@b25-ol-0-0-7622],[@b26-ol-0-0-7622]) and it is considered a TKI acquired resistance mutation ([@b27-ol-0-0-7622]--[@b29-ol-0-0-7622]). In this study, a new mutation, M793K, was detected in 7 out of 354 NSCLC patients. These 7 patients gained drug resistance following their treatment with gefitinib, and no other previously identified drug resistance mutations were detected in these patients.

The docking analysis of gefitinib and EGFR kinase domain with/without T790M or M793K mutations demonstrated that gefitinib was always identified in the cleft between the N-lobe and C-lobe of the EGFR kinase domain, which is also the location of M793K. TKIs form direct H-bonds with M793 and T790 ([@b30-ol-0-0-7622]--[@b33-ol-0-0-7622]). Computational simulation and prediction methodologies have predicted that M793 forms a high proportion of these H-bonds with inhibitors ([@b34-ol-0-0-7622]) and M793K was previously predicted to be associated with drug resistance (resistance score, 0.057) ([@b35-ol-0-0-7622]). The full fitness score between gefitinib and the EGFR M793K structure was higher than that between gefitinib and the wild type EGFR structure, and between gefitinib and the EGFR T790M structure. These findings indicate that M793K reduces the binding affinity between gefitinib and EGFR and may induce the development of the resistance to TKI treatment.

In coclusion, the present study presents a complete picture of exon 18--21 EGFR mutations based on 354 Chinese patients with NSCLC, and investigates the association between EGFR mutations with sex, age, smoking history, and histology. The EGFR M793K mutation was identified for the first time in NSCLC patients and may have been associated with resistance to TKI treatment. This finding laid the basis for the further investigation of the association between M793K mutation and TKI treatment clinical outcomes.
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###### 

Primers for the detection of EGFR mutations in patients with non-small cell lung cancer.

  Primer name   Primer sequence, 5′-3′
  ------------- ------------------------
  EGFR(E18)-F   GAAGCTCCCAACCAAGCTCT
  EGFR(E18)-R   CTCCCCACCAGACCATGAGA
  EGFR(E19)-F   TGCCAGTTAACGTCTTCCTTC
  EGFR(E19)-R   CCCACACAGCAAAGCAGAAA
  EGFR(E20)-F   CCAGGAAGCCTACGTGATGG
  EGFR(E20)-R   GACATAGTCCAGGAGGCAGC
  EGFR(E21)-F   GTGAAAACACCGCAGCATGT
  EGFR(E21)-R   GCCACCTCCTTACTTTGCCT

EGFR, epidermal growth factor receptor; E, exon; F, forward; R, reverse.

###### 

Characteristics of 354 patients with non-small cell lung cancer.

  Characteristic              Patients, n (%)
  --------------------------- -----------------
  Sex, n (%)                  
    Male                      201 (56.78)
    Female                    153 (43.22)
  Age, years                  
    ≥60, n (%)                209 (59.04)
    \<60, n (%)               145 (40.96)
    Median (range)            62 (32--92)
  Smoking status, n (%)       
    Smokers                   174 (49.15)
    Non-smokers               180 (50.85)
  Histology type, n (%)       
    Adenocarcinoma            290 (81.92)
    Squamous cell carcinoma   60 (16.95)
    Large cell carcinoma      4 (1.13)

###### 

Summary of epidermal growth factor receptor exon 18--21 mutations in 354 non-small cell lung cancer tissue samples.

  Exon   Mutation          Frequency (%)
  ------ ----------------- ---------------
  18     V689M             0.28
  18     P691S             0.28
  18     P694L             0.28
  18     Q701L             0.56
  18     Q701R             0.28
  18     Q701X             0.28
  18     L703P             0.28
  18     R705G             0.56
  18     L707S             0.56
  18     K708E             0.56
  18     K708R             0.28
  18     E709_710T\>D      0.28
  18     E709K             0.28
  18     E711A             0.28
  18     E711V             0.28
  18     F712L             0.28
  18     F712Q             0.28
  18     K713H             0.56
  18     I715V             0.56
  18     V717A             0.28
  18     G719A             0.28
  18     G719D             0.28
  18     G719V             0.28
  18     S720P             0.56
  18     S720T             0.28
  18     G721S             0.28
  18     F723C             0.28
  18     F723L             0.56
  18     K728M             0.28
  18     K728T             0.28
  19     L730I             1.13
  19     I732V             0.28
  19     E734A             0.28
  19     E734R             0.85
  19     G735D             0.28
  19     E736V             0.28
  19     K737R             0.28
  19     V738L             0.28
  19     I740F             0.28
  19     P741R             0.28
  19     P741S             0.28
  19     V742A             0.56
  19     I744V             0.28
  19     K745R             0.28
  19     E746_A750del      8.47
  19     E746_E749del      0.28
  19     E746_S752\>A      0.28
  19     E746_S752\>D      0.56
  19     E746_T751\>A      1.69
  19     E746_T751del      0.28
  19     E746K             0.56
  19     L747_750A\>S      0.28
  19     L747_A750del      0.85
  19     L747_E749del      0.56
  19     L747_P753\>S      1.98
  19     L747_T751del      1.13
  19     R748G             0.28
  19     E749G             0.28
  19     S752_I759del      0.85
  19     P753T             0.28
  19     K754R             0.28
  19     A755V             0.28
  19     K757E             0.28
  19     K757T             0.28
  19     E758K             0.28
  19     L760P             0.85
  19     D761H             0.28
  19     D761Q             0.56
  20     A763T             0.28
  20     V765A             0.28
  20     A767S             0.28
  20     A767V             0.28
  20     S768_V769insGGQ   0.28
  20     S768I             0.28
  20     S768R             0.28
  20     D770_N771insG     0.28
  20     D770_N771insTP    0.28
  20     N771\>KT          0.28
  20     C775Y             0.28
  20     R776A             0.28
  20     R776H             0.28
  20     L777C             0.28
  20     L777P             0.28
  20     L778Q             0.28
  20     G779D             0.28
  20     I780S             0.28
  20     T783A             0.28
  20     S784P             0.28
  20     V786A             0.28
  20     Q787Q             3.11
  20     L788Q             0.28
  20     I789F             0.28
  20     T790M             1.13
  20     Q791L             0.28
  20     M793K             1.98
  20     M793L             0.28
  20     P794L             0.28
  20     F795L             0.56
  20     C797S             0.28
  20     L799Q             1.41
  20     V802A             0.28
  20     L814M             0.28
  21     M825T             0.28
  21     N826H             0.28
  21     N826S             0.28
  21     E829D             0.28
  21     V834A             0.56
  21     V834M             0.28
  21     R836H             0.28
  21     A840T             0.28
  21     V845A             0.28
  21     K846I             1.13
  21     Q849L             0.28
  21     Q849R             0.28
  21     H850Y             0.28
  21     I853T             0.28
  21     T854A             0.28
  21     D855A             0.28
  21     F856L             1.13
  21     G857E             0.28
  21     G857W             0.56
  21     L858H             0.28
  21     L858P             0.28
  21     L858R             10.17
  21     K860R             0.28
  21     K860Tfs           0.28
  21     L861Q             0.56
  21     L862Q             0.28
  21     G863C             0.28
  21     G863S             0.28
  21     G863V             0.28
  21     E865G             0.28
  21     E865K             0.56
  21     E866G             0.28
  21     E866R             0.56
  21     E866X             0.28
  21     K867D             0.28
  21     K867I             0.28
  21     K867N             0.85
  21     E868D             0.28
  21     E868V             0.28
  21     H870Q             0.28
  21     H870R             0.28
  21     A871T             0.28
  21     A871V             0.28
  21     G873E             0.28

###### 

Association of EGFR mutations with the clinicopathological features of patients with non-small cell lung cancer.

                         EGFR status, n   Univariate   Multivariate                                            
  ---------------------- ---------------- ------------ ---------------------- --------- ---------------------- -------
  Sex                                                                                                          
    Male                 78               123          Ref.                             Ref.                   
    Female               92               61           2.378 (1.547--3.657)   \<0.001   1.929 (1.072--3.506)   0.029
  Age, years                                                                                                   
    ≥60                  85               124          Ref.                             Ref.                   
    \<60                 85               60           2.067 (1.344--3.179)   0.001     1.869 (1.200--2.923)   0.006
  Smoking status                                                                                               
    Smoker               70               104          Ref.                             Ref.                   
    Non-smoker           100              80           1.857 (1.218--2.833)   0.005     1.018 (0.564--1.815)   0.952
  Pathology                                                                                                    
    Non-ADC              17               47           Ref.                             Ref.                   
    ADC                  153              137          3.088 (1.693--5.630)   \<0.001   2.352 (1.275--4.497)   0.007
  Smokers                                                                                                      
    Male                 63               94           Ref.                                                    
    Female               7                10           1.044 (0.378--2.888)   1                                
  Non-smokers                                                                                                  
    Male                 15               29           Ref.                                                    
    Female               85               51           3.222 (1.579--6.577)   0.002                            
  ADC                                                                                                          
    Male                 65               82           Ref.                                                    
    Female               88               55           2.019 (1.264--3.225)   0.005                            
  SCC                                                                                                          
    Male                 12               38           Ref.                                                    
    Female               4                6            2.111 (0.509--8.751)   0.514                            
  Non-smokers with ADC                                                                                         
    Male                 14               20           Ref.                                                    
    Female               81               47           2.462 (1.138--5.327)   0.033                            
  Male                                                                                                         
    Smokers              63               94           Ref.                                                    
    Non-smokers          15               29           0.772 (0.383--1.555)   0.582                            
  Female                                                                                                       
    Smokers              7                10           Ref.                                                    
    Non-smokers          85               51           2.381 (0.853--6.645)   0.153                            
  ≥60                                                                                                          
    Smokers              40               72           Ref.                                                    
    Non-smokers          45               52           1.558 (0.894--2.715)   0.154                            
  \<60                                                                                                         
    Smokers              30               32           Ref.                                                    
    Non-smokers          55               28           2.096 (1.067--4.114)   0.046                            
  ADC                                                                                                          
    Smokers              58               70           Ref.                                                    
    Non-smokers          95               67           1.711 (1.072--2.732)   0.032                            
  SCC                                                                                                          
    Smokers              11               31           Ref.                                                    
    Non-smokers          5                13           1.084 (0.314--3.745)   1                                
  Males with ADC                                                                                               
    Smokers              51               62           Ref.                                                    
    Non-smokers          14               20           0.851 (0.391--1.851)   0.833                            
  Females with ADC                                                                                             
    Smokers              7                8            Ref.                                                    
    Non-smokers          81               47           1.970 (0.671--5.778)   0.331                            
  ≥60 male                                                                                                     
    Smokers              36               63           Ref.                                                    
    Non-smokers          7                22           0.557 (0.217--1.431)   0.316                            
  \<60 female                                                                                                  
    Smokers              3                1            Ref.                                                    
    Non-smokers          47               21           0.746 (0.073--7.598)   1                                
  ≥60 ADC                                                                                                      
    Smokers              33               45           Ref.                                                    
    Non-smokers          43               43           1.364 (0.736--2.527)   0.407                            
  \<60 ADC                                                                                                     
    Smokers              25               25           Ref.                                                    
    Non-smokers          52               24           2.167 (1.038--4.522)   0.059                            

EGFR, epidermal growth factor receptor; OR, odds ratio; CI, confidence interval; Ref., reference value; ADC, adenocarcinoma; SCC, squamous cell carcinoma.

###### 

Full fitness score between gefitinib and EGFR wild type and EGFR T790M and M793K mutants, as predicted by Swiss-Dock.

  EGFR        Full fitness score (kcal/mol)
  ----------- -------------------------------
  Wild type   (−2,196.87; −2,160.79)
  T790M       (−1,805.53; −1,759.77)
  M793K       (−1,791.71; −1,756.65)

EGFR, epidermal growth factor receptor.

[^1]: Contributed equally
